AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: Market Implications

AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca is currently recruiting participants for a Phase III clinical study titled A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure. The study aims to assess the efficacy, safety, and tolerability of combining Baxdrostat with Dapagliflozin, compared to Dapagliflozin alone, in improving renal outcomes and reducing cardiovascular mortality in patients with chronic kidney disease (CKD) and high blood pressure (HTN).

The intervention being tested involves the use of Baxdrostat combined with Dapagliflozin, both of which are drugs intended to improve kidney function and reduce cardiovascular mortality in patients with CKD and HTN.

This study is designed as an interventional, randomized, double-blind, placebo-controlled trial with a parallel-group model. It involves quadruple masking to ensure unbiased results, with the primary purpose being treatment.

The study began on March 3, 2025, and is currently recruiting participants. The last update was submitted on July 1, 2025. These dates are crucial as they mark the progress and current status of the trial, which is essential for tracking its development and potential market impact.

This clinical study update could potentially influence AstraZeneca’s stock performance positively, as successful results might enhance investor confidence and market position, especially in the competitive pharmaceutical industry focused on CKD and cardiovascular treatments.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.